Conclusions: Our data suggest a better outcome on ensuing systemic therapies after IT. Further prospective investigations are needed to select the subset of patients who are more prone to a re-sensitization to CCT and to understand the mechanisms underlying. Legal entity responsible for the study: Cl ınica Universidad de Navarra. Funding: Has not received any funding.
Background: The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies such as cetuximab is a major clinical problem. This study aims to unravel resistance mechanisms by combining whole-exome sequencing (WES) and tumour kinase profiling. Based on the genetic and tumour kinase profile, new combination treatments can be designed to overcome therapy resistance. Methods: Acquired cetuximab resistant HNSCC cell lines (SC263-R and SCC22b-R) were generated by chronically exposing initially sensitive cell lines to cetuximab. In parallel, control cell lines (SC263-PBS and SCC22b-PBS) were established by exposing these cells to the vehicle control. DNA samples were sequenced using Illumina's HiSeq 1500 platform and variant calling was performed. Proteome Profiler Human PhosphoKinase Antibody Array kit (R&D Systems) was used to determine the relative levels of protein kinase phosphorylation in sensitive and acquired resistant cell lines after cetuximab treatment. Results: Variant calling in cetuximab sensitive and acquired resistant cell lines demonstrated 10 and 1 novel single-nucleotide variants (SNVs) in SC263-R and SCC22b-R, respectively. Based on gene functions, these SNVs might be responsible for resistance to cetuximab treatment. Phospho-kinase analysis showed increased phosphorylation of Akt1/2/3 after cetuximab treatment in acquired resistant cells compared to sensitive cells. As such, combining cetuximab with an Akt1/2/3 inhibitor could be an interesting new combination treatment. Results obtained from WES and tumour kinase profiling will be further validated using Sanger sequencing and western blot, respectively. Conclusions: This study demonstrated that resistance mechanisms for EGFR-targeted therapy can be identified through genetic and tumour kinase profiling. Our results showed that SNVs and increased Akt1/2/3 phosphorylation may lead to acquired cetuximab resistance. Personalised therapy using combinations of targeted therapies based on the molecular profile of the tumour may achieve the much-needed progress in HNSCC treatment. Legal entity responsible for the study: University of Antwerp. Background: Although knowledge of the molecular landscape in gynecologic tumors is increasing, the clinical impact of an extensive screening remains unclear. The aim of this monocentric study was to characterize molecular alterations in advanced gynecologic tumors, and to evaluate the clinical benefit of corresponding targeted agents. Methods: Advanced gynecologic cancers were prospectively included in our molecular screening program. DNA and RNA extracted from tissue samples were analyzed by next generation sequencing, and when necessary, by comparative genomic hybridization array, polymerase chain reaction, fluorescence in situ hybridization and immunohistochemistry. Patients were enrolled, when possible, in early trials according to our molecular tumor board recommendations. We assessed clinical benefit with disease control rate (objective response and stable disease) and Growth Modulation Index (GMI defined as: time to progression under the early phase trial treatment/time to progression of the previous line of treatment) > 1.3. Results: 245 patients (ovary, n ¼ 135; endometrium, n ¼ 57; cervix, n ¼ 37; uterus, n ¼ 12; vulva, n ¼ 3; vagina, n ¼ 1) were recruited from February 2013 to May 2017. 115 (47%) patients had at least one actionable alteration. 131 different molecular alterations were found. The most frequent actionable alterations were PIK3CA (n ¼ 45), hormone receptor expression (n ¼ 38), KRAS (n ¼ 23), BRCA1 and BRCA2 (n ¼ 18) and HER2 (n ¼ 16). Median number of previous lines of treatment was 2. 47 patients received a treatment matched with tumor molecular profile. Main reasons for noninclusion were non-progressive disease (n ¼ 24, 51%) and general status deterioration or death (n ¼ 13, 28%). Median progression-free survival was 12,1 weeks (95% CI 8,3-16). Median overall survival was 34,6 weeks (95% CI 46,9-104,6). Disease control rate was 38%, and 14 % of patients had a GMI > 1.3. Conclusions: Molecular profiling for gynecologic tumors is feasible and detects molecular alterations with a positive clinical impact. The yield of this procedure could be improved by higher throughput sequencing techniques, wider access to genotypematched treatments, and an earlier screening during the course of the disease. Legal entity responsible for the study: Institut Bergonié. Funding: Has not received any funding. Disclosure: T. Grellety: Paid for consulting role for Novartis during the past 2 years. All other authors have declared no conflicts of interest. Background: BRCA1/2 germline mutations accompanied by somatic mutations in p53 associated genes are associated with increased risk of developing breast cancer (BC). Genes acting upstream of p53, or participating in growth arrest following DNA damage such as the BRCA1-interacting protein, ZNF350, may modify the risk of BC in women with mutant BRCA1/2 through mediating BRCA1-induced transcriptional repression of several tumor suppressor genes. As a potential BC susceptibility gene, single nucleotide polymorphisms (SNPs) may influence transcriptional repression of ZNF350 target genes and individuals' BC risk. Moreover, rs2278414 (G/A) SNP in ZNF350 3'UTR was associated with BC onset in BRCA1/2 carriers ("A" allele hazard ratio¼ 2.47). We aimed at regulating rs2278414 SNP in ZNF350 by miRNAs in BC as it has never been investigated in such context. Methods: In-silico analysis predicted miRNAs targeting ZNF350. Wild-type constructs containing "A" allele or ancestral "G" allele of rs2278414 SNP in ZNF350 3 0 UTR were designed. miR-target binding regions were inserted downstream to luciferase reporter gene in pmirGLO Luciferase microRNA Target Expression Vector. MDA-MB-231 BC cells were transfected with "G" SNP, or a construct with site-specific binding). After luciferase activity was Wound-healing and colony MB-231. Results: Using bioinformatics http://mirdsnp.ccr.buffalo rs2278414 "A" allele, but not Functionally, miR-150-5p repress the ancestral protective "G" allele. Functional analysis of miRNA-150-5p showed a significant decrease in MDA-MB-231 cells' wound closure and clonogenicity. Conclusions: The novel tumor suppressor miR-150-5p downregulates rs2278414 "A" allele in ZNF350 3'UTR thus decreasing BC risk. Legal entity responsible for the study: German University in Cairo. Background: Wnt/bb-catenin-signaling pathway is the principal force of intestinal hemostasis and morphogenesis. Aberrant activity of this pathway is highly implicated in cancer development, particularly in colorectal cancer (CRC). Although Wnt/b-catenin pathway is a well-studied pathway, the precise molecular mechanisms involved in the nuclear interactions of b-catenin with DNA-binding transcription factors (other than TCF4) are still under debates. Human FLYWCH1 has been first characterized and identified in our lab as a novel transcription factor, which interacts with nuclear b-catenin and modulates its transcriptional activity (Muhammed et al., under publication) . 
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